Document Detail

The cost-effectiveness of targeted or universal screening for vasa praevia at 18-20 weeks of gestation in Ontario.
MedLine Citation:
PMID:  20560948     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: To estimate the cost-effectiveness of targeted and universal screening for vasa praevia at 18-20 weeks of gestation in singleton and twin pregnancies. DESIGN: Cost-utility analysis based on a decision-analytic model comparing relevant strategies and life-long outcomes for mother and infant(s). SETTING: Ontario, Canada. POPULATION: A cohort of pregnant women in 1 year. METHODS: We constructed a decision-analytic model to estimate the lifetime incremental costs and benefits of screening for vasa praevia. Inputs were estimated from the literature. Costs were collected from the London Health Sciences Centre, the Ontario Health Insurance Program, and other sources. We used one-way, scenario and probabilistic sensitivity analysis to determine the robustness of the results. MAIN OUTCOME MEASURES: Incremental costs, life expectancy, quality-adjusted life-years (QALY) and incremental cost-effectiveness ratio (ICER). RESULTS: Universal transvaginal ultrasound screening of twin pregnancies has an ICER of $5488 per QALY-gained. Screening all singleton pregnancies with the risk factors low-lying placentas, in vitro fertilisation (IVF) conception, accessory placental lobes, or velamentous cord insertion has an ICER of $15,764 per QALY-gained even though identifying some of these risk factors requires routine use of colour Doppler during transabdominal examinations. Screening women with a marginal cord insertion costs an additional $27,603 per QALY-gained. Universal transvaginal screening for vasa praevia in singleton pregnancies costs $579,164 per QALY compared with targeted screening. CONCLUSIONS: Compared with current practice, screening all twin pregnancies for vasa praevia with transvaginal ultrasound is cost-effective. Among the alternatives considered, the use of colour Doppler at all transabdominal ultrasound examinations of singleton pregnancies and targeted use of transvaginal ultrasound for IVF pregnancies or when the placenta has been found to be associated with one or more risk factors is cost-effective. Universal screening of singleton pregnancies is not cost-effective compared with targeted screening.
L E Cipriano; W H Barth; G S Zaric
Related Documents :
1377388 - Improved performance in a prenatal screening programme for down's syndrome incorporatin...
18249458 - Detection and care of women with gestational diabetes mellitus from early weeks of preg...
16806218 - Second-trimester double or triple screening for down syndrome: a comparison of chinese ...
23175668 - Gestational age-dependent changes in gene expression of metabolic enzymes and transport...
18399968 - The optimized v-v interval determined by interventricular conduction times versus invas...
19587688 - Parathyroid surgery in pregnancy: review of the literature and localization by aspirati...
Publication Detail:
Type:  Evaluation Studies; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't     Date:  2010-06-18
Journal Detail:
Title:  BJOG : an international journal of obstetrics and gynaecology     Volume:  117     ISSN:  1471-0528     ISO Abbreviation:  BJOG     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-07-07     Completed Date:  2010-11-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100935741     Medline TA:  BJOG     Country:  England    
Other Details:
Languages:  eng     Pagination:  1108-18     Citation Subset:  AIM; IM    
Department of Management Science & Engineering, Stanford University, Stanford, CA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cost-Benefit Analysis
Infant, Newborn
Life Expectancy
Ontario / epidemiology
Pregnancy Outcome / epidemiology
Pregnancy Trimester, Second
Pregnancy, Multiple
Quality-Adjusted Life Years
Ultrasonography, Prenatal / economics*,  methods
Vasa Previa / economics,  epidemiology,  ultrasonography*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Changes in the treatment of endometrial cancer.
Next Document:  A new concept for non-invasive renal tumour ablation using real-time MRI-guided radiation therapy.